Previous Close | 29.60 |
Open | 29.60 |
Bid | 29.00 x 255900 |
Ask | 29.10 x 42900 |
Day's Range | 28.50 - 29.60 |
52 Week Range | 13.60 - 70.00 |
Volume | |
Avg. Volume | 650,566 |
Market Cap | 310.765M |
Beta (5Y Monthly) | 0.93 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.19 |
Earnings Date | Mar 19, 2024 - Mar 22, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for BLRX.TA
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent, "Process for Manufacturing Peptide," covering a method of manufacturing motixafortide (BL-8040) that is suitable for large scale production.
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that the first patient has been dosed in the randomized CheMo4METPANC Phase 2 combination clinical trial evaluating the company's CXCR4 inhibitor motixafortide, the PD-1 inhibitor cemiplimab, and standard of care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic c
By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT Subgroup Analyses of Genesis Trial Data at ASTCT & CIBMTR Washington University School of Medicine’s Zachary Crees, MD and BioLineRx’ (NASDAQ:BLRX) Ella Sorani, PhD descended on San Antonio, Texas last week to participate in poster presentations for the Transplantation & Cellular Therapy Meetings of the American